vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and WEIBO Corp (WB). Click either name above to swap in a different company.
WEIBO Corp is the larger business by last-quarter revenue ($1.3B vs $950.5M, roughly 1.4× Astrana Health, Inc.). WEIBO Corp runs the higher net margin — 35.7% vs 0.7%, a 35.0% gap on every dollar of revenue. Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 22.6%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
Weibo Corporation is a Chinese social network company known for the microblogging website Sina Weibo. It is based in Beijing, China.
ASTH vs WB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $1.3B |
| Net Profit | $6.6M | $458.3M |
| Gross Margin | — | — |
| Operating Margin | 1.9% | 29.1% |
| Net Margin | 0.7% | 35.7% |
| Revenue YoY | 42.9% | — |
| Net Profit YoY | 184.4% | — |
| EPS (diluted) | $0.12 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $950.5M | — | ||
| Q3 25 | $956.0M | $1.3B | ||
| Q2 25 | $654.8M | $841.7M | ||
| Q1 25 | $620.4M | $396.9M | ||
| Q4 24 | $665.2M | — | ||
| Q3 24 | $478.7M | $1.3B | ||
| Q2 24 | $486.3M | $833.4M | ||
| Q1 24 | $404.4M | $395.5M |
| Q4 25 | $6.6M | — | ||
| Q3 25 | $373.0K | $458.3M | ||
| Q2 25 | $9.4M | $234.8M | ||
| Q1 25 | $6.7M | $108.1M | ||
| Q4 24 | $-7.8M | — | ||
| Q3 24 | $16.1M | $297.4M | ||
| Q2 24 | $19.2M | $164.6M | ||
| Q1 24 | $14.8M | $51.1M |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 2.0% | 29.1% | ||
| Q2 25 | 3.1% | 30.4% | ||
| Q1 25 | 3.3% | 27.8% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.9% | 29.0% | ||
| Q2 24 | 6.2% | 28.2% | ||
| Q1 24 | 7.5% | 25.2% |
| Q4 25 | 0.7% | — | ||
| Q3 25 | 0.0% | 35.7% | ||
| Q2 25 | 1.4% | 27.9% | ||
| Q1 25 | 1.1% | 27.2% | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 3.4% | 22.9% | ||
| Q2 24 | 3.9% | 19.8% | ||
| Q1 24 | 3.7% | 12.9% |
| Q4 25 | $0.12 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.19 | — | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $0.33 | — | ||
| Q2 24 | $0.40 | — | ||
| Q1 24 | $0.31 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $779.3M | $3.9B |
| Total Assets | $2.2B | $6.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $429.5M | — | ||
| Q3 25 | $463.4M | $1.1B | ||
| Q2 25 | $342.1M | $1.2B | ||
| Q1 25 | $260.9M | $1.2B | ||
| Q4 24 | $290.8M | — | ||
| Q3 24 | $350.3M | — | ||
| Q2 24 | $327.7M | $1.9B | ||
| Q1 24 | $337.3M | $2.1B |
| Q4 25 | $779.3M | — | ||
| Q3 25 | $775.5M | $3.9B | ||
| Q2 25 | $765.5M | $3.6B | ||
| Q1 25 | $745.4M | $3.5B | ||
| Q4 24 | $712.7M | — | ||
| Q3 24 | $704.6M | — | ||
| Q2 24 | $678.9M | $3.4B | ||
| Q1 24 | $653.5M | $3.3B |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | $6.9B | ||
| Q2 25 | $1.4B | $6.5B | ||
| Q1 25 | $1.3B | $6.7B | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | $7.1B | ||
| Q1 24 | $1.2B | $7.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | — |
| Free Cash FlowOCF − Capex | $-6.0M | — |
| FCF MarginFCF / Revenue | -0.6% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | -0.44× | — |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | — | ||
| Q3 25 | $10.0M | — | ||
| Q2 25 | $90.9M | — | ||
| Q1 25 | $16.6M | — | ||
| Q4 24 | $-10.9M | — | ||
| Q3 24 | $34.0M | — | ||
| Q2 24 | $23.2M | — | ||
| Q1 24 | $6.0M | — |
| Q4 25 | $-6.0M | — | ||
| Q3 25 | $7.4M | — | ||
| Q2 25 | $89.5M | — | ||
| Q1 25 | $13.6M | — | ||
| Q4 24 | $-13.5M | — | ||
| Q3 24 | $31.7M | — | ||
| Q2 24 | $20.4M | — | ||
| Q1 24 | $5.6M | — |
| Q4 25 | -0.6% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | -2.0% | — | ||
| Q3 24 | 6.6% | — | ||
| Q2 24 | 4.2% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | -0.44× | — | ||
| Q3 25 | 26.69× | — | ||
| Q2 25 | 9.65× | — | ||
| Q1 25 | 2.48× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 0.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
WB
| Income from operations | $373.2M | 29% |
| Shares used in computing diluted net income per share attributable to Weibos shareholders | $268.1M | 21% |
| Shares used in computing basic net income per share attributable to Weibos shareholders | $238.6M | 19% |
| Value-added services | $186.1M | 14% |
| Less: Income tax expenses | $113.2M | 9% |
| Investment related income, net | $45.0M | 4% |
| Product development | $16.7M | 1% |
| General and administrative | $10.6M | 1% |
| Sales and marketing | $7.1M | 1% |
| Accretion to redeemable non-controlling interests | $3.0M | 0% |
